Insider Selling: Vera Therapeutics (NASDAQ:VERA) Insider Sells 2,187 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) insider William Turner sold 2,187 shares of Vera Therapeutics stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $91,810.26. Following the completion of the transaction, the insider owned 45,313 shares of the company’s stock, valued at $1,902,239.74. This trade represents a 4.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Vera Therapeutics Stock Down 1.6%

Vera Therapeutics stock traded down $0.69 during mid-day trading on Wednesday, reaching $41.68. 776,869 shares of the company’s stock were exchanged, compared to its average volume of 897,432. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $56.05. The company has a market cap of $2.92 billion, a P/E ratio of -10.45 and a beta of 1.16. The company has a fifty day moving average of $46.63 and a 200-day moving average of $35.30.

Analyst Ratings Changes

VERA has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. JPMorgan Chase & Co. lowered their price objective on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Friday, November 28th. Finally, Pivotal Research set a $73.00 price target on shares of Vera Therapeutics in a research note on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.18.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its stake in Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Vera Therapeutics during the fourth quarter worth approximately $46,000. Quantbot Technologies LP purchased a new stake in shares of Vera Therapeutics during the 2nd quarter worth approximately $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Vera Therapeutics in the 4th quarter valued at $71,000. Finally, Virtus Investment Advisers LLC boosted its holdings in shares of Vera Therapeutics by 14.8% in the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after buying an additional 539 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.